Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > BLCO Bausch + Lomb Corp. > Company Executives
BLCO Bausch + Lomb Corp.
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Joseph C. PapaChairman of the Board and Chief Executive Officer22.89M----66male05/06/2022
Mr. Sam A. EldessoukyChief Financial Officer4.33M----49male05/06/2022
Dr. Yehia HashadExecutive Vice President of Research & Development and Chief Medical Officer------55male05/06/2022
Ms. Christina M. AckermannExecutive Vice President, General Counsel and President, Ophthalmic Pharmaceuticals4.57M----57female05/06/2022
Mr. Joseph F. GordonPresident, Global Consumer, Surgical and Vision Care3.24M----58male05/06/2022
Mr. Brett M. IcahnDirector--------male06/23/2022
Mr. John A. PaulsonDirector------66male05/06/2022
Mr. Gary HuDirector--------male06/23/2022
Mr. Richard U. De SchutterIndependent Director------81male05/06/2022
Mr. Russel C. RobertsonIndependent Director------74male05/06/2022
Dr. Andrew C. von Eschenbach, M.D.Independent Director------80male05/06/2022
Ms. Sarah B. KavanaghIndependent Director------65female05/06/2022
Mr. Thomas W. Ross, SrLead Independent Director------71male05/06/2022
Ms. Nathalie BernierIndependent Director------58female05/06/2022
Company Overview More
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
CEO: Papa, Joseph C.
Market: NYSE
Futu Hot List
SymbolLatest price%Chg


Back to the Top